878 results on '"Horny, Hans-Peter"'
Search Results
2. Diagnostik und Therapie der systemischen Mastozytose
3. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
4. World Health Organization Classification and Diagnosis of Mastocytosis: Update 2023 and Future Perspectives
5. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
6. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
7. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
8. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
9. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
10. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
11. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
12. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
13. Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis
14. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
15. Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
16. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
17. Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis
18. Mastocytosis
19. History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis
20. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
21. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
22. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity
23. Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis
24. Mastozytosen
25. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
26. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis
27. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
28. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
29. P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
30. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome
31. History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis
32. Mastocytosis
33. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
34. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers
35. Mastozytosen
36. Supplemental Table S3 from Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
37. Data from Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
38. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy
39. Diagnostik und Therapie der systemischen Mastozytose
40. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
41. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis
42. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis
43. Contributors
44. Mast Cells and Mastocytosis
45. Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features
46. An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety
47. Response and Resistance to Cladribine in Patients with Advanced Systemic Mastocytosis: A Registry-Based Analysis
48. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes
49. Systemic Mastocytosis Associated with Lymphoproliferative Disorders (SM-AHNMD)
50. Diagnostic Criteria and Classification of Myelodysplastic Syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.